Breaking News

Tigermed Gains Majority Stake in Frontage

August 5, 2014

Partnership establishes global clinical trial network

Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. have completed an investment agreement, following approval by the China Securities and Regulatory Commission, under which Tigermed has acquired a majority stake in Frontage, a provider of bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharma companies. Tigermed provides outsourced clinical development services across China and Asia Pacific regions.
 
Frontage will continue to operate independently, and will retain its name, management team and operations facilities.
 
“Our strategic partnership with Frontage firmly establishes our global clinical trial network,” said Dr. Xiaoping Ye, founder and chief executive officer of Tigermed. “The two companies share similar philosophies and operational approaches, which combined with additional complementary strengths in research integrity and reliability will now benefit clients on a much larger scale.”
 
“Joining efforts with Tigermed allows us to expand our geographic range and align our early development services with Tigermed’s late phase clinical operations for a scope that will serve clients looking for full-service, high quality, global drug development resources,” said Song Li, founder and chief executive officer of Frontage.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems